Clinical Trial Update: Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating safety, tolerability, and efficacy of two daily doses of P2B001 in early Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• P2B001

Snippet

Sponsor: Pharma Two B Ltd. | Conditions: Parkinson's Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-04-07